Redeye comments on Ultimovacs’ Q3 2023 report, with recently presented NIPU survival data paving UV1’s path to phase III trials in mesothelioma. All eyes are now set on INITIUM top-line data, set for communication in March or April 2024e. We do some housekeeping in our model and adjust our valuation.